A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Pediatrix Medical Group, Inc.
MD
$2.2B
Mkt Cap
$26.26
+2.66%
Pediatrix Medical Group, Inc. (MD) has a current P/E ratio of 13.5, compared to its historical median P/E of 16.6. The stock is currently considered Fair based on its historical valuation range.
Pediatrix Medical Group, Inc. (MD) has a 5-year average return on invested capital (ROIC) of 5.7%. This is below average and may indicate limited pricing power.
Pediatrix Medical Group, Inc. (MD) has a market capitalization of $2.2B. It is classified as a mid-cap stock.
Pediatrix Medical Group, Inc. (MD) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 4.95%.
Based on historical P/E analysis, Pediatrix Medical Group, Inc. (MD) appears fair. The current P/E of 13.5 is 19% below its historical median of 16.6. The estimated fair value CAGR (P/E method) is -14.5%.
Pediatrix Medical Group, Inc. (MD) operates in the Services-Hospitals industry, within the Healthcare sector.
Pediatrix is a leading provider of physician services including newborn, maternal-fetal, and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in 37 states. During 2024, we formalized our practice portfolio management plans, resulting in a decision to exit almost all of our affiliated office-based practices, other than maternal-fetal medicine. As of December 31, 2024, these plans were completed. Additionally, we exited our primary and urgent care service line during 2024 based on a review of the cost and time that would be required to build the platform to scale. At December 31, 2025, our national network comprised approximately 2,295 affiliated physicians, including 1,350 physicians who provide neonatal clinical care, primarily within hospital-based neonatal intensive care units (“NICUs”), to babies born prematurely or with medical complications.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.9B | 1.9B | 2.0B | 2.0B | 2.0B | 1.9B |
| Net Income | 174M | 165M | -99M | -60M | 66M | 131M |
| EPS | $2.05 | $1.94 | $-1.19 | $-0.73 | $0.79 | $1.53 |
| Free Cash Flow | 254M | 253M | 185M | 104M | 137M | 44M |
| ROIC | 14.7% | 15.3% | -7.3% | 0.5% | 8.8% | 11.1% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.67 | 0.76 | 0.89 | 0.84 | 0.82 | 1.18 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 218M | 209M | -69M | 7.3M | 173M | 203M |
| Operating Margin | 11.3% | 10.9% | -3.4% | 0.4% | 8.8% | 10.6% |
| ROE | 19.8% | 20.3% | -13.0% | -7.1% | 7.4% | 14.6% |
| Shares Outstanding | 82M | 85M | 83M | 83M | 84M | 86M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 2.4B | 2.8B | 3.2B | 3.5B | 3.5B | 1.8B | 1.7B | 1.9B | 2.0B | 2.0B | 2.0B | 1.9B | 1.9B |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | 248M | 306M | 373M | 386M | 404M | 245M | 249M | 263M | 231M | 228M | 238M | 241M | 242M |
| EBIT | 513M | 558M | 572M | 455M | 432M | -1.1B | 98M | 203M | 173M | 7.3M | -69M | 209M | 218M |
| Op. Margin | 21.0% | 20.1% | 18.0% | 13.2% | 12.5% | -63.8% | 5.7% | 10.6% | 8.8% | 0.4% | -3.4% | 10.9% | 11.3% |
| Net Income | 317M | 336M | 325M | 320M | 269M | -1.5B | -796M | 131M | 66M | -60M | -99M | 165M | 174M |
| Net Margin | 13.0% | 12.1% | 10.2% | 9.3% | 7.8% | -84.2% | -45.9% | 6.9% | 3.4% | -3.0% | -4.9% | 8.6% | 9.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 1.5B | 74M | 22M | 27M | 151M | 205M | 173M | 21M |
| Returns on Capital | |||||||||||||
| ROIC | 11.6% | 9.7% | 7.9% | 6.5% | 7.4% | -46.4% | 4.4% | 11.1% | 8.8% | 0.5% | -7.3% | 15.3% | 14.7% |
| ROE | 13.8% | 14.3% | 12.5% | 11.0% | 8.7% | -99.9% | -106.6% | 14.6% | 7.4% | -7.1% | -13.0% | 20.3% | 19.8% |
| ROA | 9.6% | 8.2% | 6.6% | 5.7% | 4.5% | -36.1% | -23.8% | 4.8% | 2.8% | -2.7% | -4.6% | 7.5% | 8.4% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 423M | 369M | 444M | 511M | 290M | 358M | 205M | 77M | 167M | 137M | 207M | 271M | 259M |
| Free Cash Flow | 405M | 342M | 405M | 485M | 241M | 326M | 176M | 44M | 137M | 104M | 185M | 253M | 254M |
| Owner Earnings | 345M | 272M | 321M | 404M | 168M | 245M | 137M | 26M | 115M | 89M | 162M | 231M | 217M |
| CapEx | 18M | 27M | 39M | 26M | 49M | 32M | 29M | 32M | 30M | 33M | 22M | 18M | 4.4M |
| Maint. CapEx | 46M | 64M | 89M | 79M | 84M | 79M | 28M | 32M | 36M | 36M | 32M | 22M | 23M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 347K | 102K | 0 | 0 | 0 | 0 | 0 |
| D&A | 46M | 64M | 89M | 79M | 84M | 79M | 28M | 32M | 36M | 36M | 32M | 22M | 23M |
| CapEx/OCF | 4.3% | 7.3% | 8.8% | 9.6% | 16.9% | 8.9% | 14.1% | 42.0% | 17.8% | 24.3% | 10.7% | 6.8% | 1.7% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 488M | 235M | 62M | 70M | 302M | 145M | 8.5M | 4.7M | 89M | 919K | 1.7M | 87M | 107M |
| Buyback Yield | 7.3% | 3.5% | 1.0% | 1.4% | 10.0% | 6.4% | 0.4% | 0.2% | 7.3% | 0.1% | 0.2% | 4.6% | 4.9% |
| Stock-Based Comp | 32M | 32M | 34M | 29M | 38M | 33M | 39M | 19M | 16M | 12M | 12M | 18M | 19M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | 881M | 1.6B | 2.4B | 2.9B | 1.2B | 1.6B | 578M | 569M | 625M | 539M | 334M | 162M | 262M |
| Cash & Equiv. | 48M | 52M | 56M | 40M | 25M | 108M | 1.1B | 387M | 9.8M | 73M | 230M | 375M | 329M |
| Long-Term Debt | 557M | 1.3B | 1.7B | 1.8B | 1.2B | 1.7B | 1.7B | 990M | 632M | 618M | 597M | 571M | 398M |
| Debt/Equity | 0.41 | 0.66 | 0.90 | 0.96 | 0.40 | 1.20 | 2.42 | 1.18 | 0.82 | 0.84 | 0.89 | 0.76 | 0.67 |
| Interest Coverage | 57.7 | 24.1 | 9.1 | 6.1 | 4.9 | -9.6 | 0.9 | 3.0 | 4.4 | 0.2 | -1.7 | 5.8 | 5.8 |
| Equity | 2.3B | 2.4B | 2.8B | 3.1B | 3.1B | 1.5B | 747M | 896M | 892M | 849M | 765M | 866M | 879M |
| Total Assets | 3.6B | 4.5B | 5.3B | 5.9B | 5.9B | 4.1B | 3.3B | 2.7B | 2.3B | 2.2B | 2.2B | 2.2B | 2.1B |
| Total Liabilities | 1.3B | 2.1B | 2.6B | 2.8B | 2.8B | 2.6B | 2.6B | 1.8B | 1.5B | 1.4B | 1.4B | 1.4B | 1.2B |
| Intangibles | 198M | 424M | 669M | 640M | 313M | 29M | 27M | 22M | 18M | 21M | 12M | 17M | 16M |
| Retained Earnings | 1.4B | 1.5B | 1.8B | 2.0B | 2.1B | 510M | -286M | -155M | -89M | -149M | -249M | -83M | -54M |
| Working Capital | 51M | 99M | 138M | 96M | 157M | 190M | 1.1B | 413M | 1.0M | 95M | 205M | 305M | 144M |
| Current Assets | 467M | 528M | 587M | 627M | 660M | 732M | 1.5B | 841M | 428M | 483M | 640M | 764M | 587M |
| Current Liabilities | 416M | 429M | 449M | 531M | 503M | 542M | 444M | 427M | 427M | 389M | 434M | 459M | 443M |
| Per Share Data | |||||||||||||
| EPS | 3.18 | 3.58 | 3.49 | 3.45 | 2.93 | -17.83 | -9.55 | 1.53 | 0.79 | -0.73 | -1.19 | 1.94 | 2.05 |
| Owner EPS | 3.46 | 2.90 | 3.44 | 4.35 | 1.83 | 2.92 | 1.64 | 0.30 | 1.37 | 1.07 | 1.95 | 2.71 | 2.64 |
| Book Value | 22.70 | 25.95 | 29.65 | 33.02 | 33.68 | 17.85 | 8.96 | 10.47 | 10.62 | 10.26 | 9.19 | 10.16 | 10.71 |
| Cash Flow/Share | 4.24 | 3.92 | 4.77 | 5.51 | 3.16 | 4.26 | 2.45 | 0.90 | 1.99 | 1.66 | 2.48 | 3.18 | 2.40 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 99.8M | 93.9M | 93.1M | 92.9M | 91.7M | 84.0M | 83.4M | 85.6M | 84.0M | 82.8M | 83.3M | 85.3M | 82.1M |
| Valuation | |||||||||||||
| P/E Ratio | 21.0 | 20.2 | 19.1 | 15.5 | 11.2 | N/A | N/A | 17.8 | 18.3 | N/A | N/A | 11.3 | 12.8 |
| P/FCF | 16.4 | 19.9 | 15.3 | 10.2 | 12.5 | 7.0 | 11.4 | 52.3 | 8.9 | 7.6 | 6.1 | 7.4 | 8.5 |
| EV/EBIT | 14.7 | 15.0 | 15.1 | 17.0 | 9.7 | N/A | 26.3 | 14.3 | 10.7 | 181.0 | N/A | 9.7 | 11.1 |
| Price/Book | 2.9 | 2.8 | 2.2 | 1.6 | 1.0 | 1.5 | 2.7 | 2.6 | 1.4 | 0.9 | 1.5 | 2.2 | 2.5 |
| Price/Sales | 2.4 | 2.5 | 2.0 | 1.5 | 1.3 | 1.3 | 0.9 | 1.3 | 0.9 | 0.6 | 0.4 | 0.7 | 1.1 |
| FCF Yield | 6.1% | 5.0% | 6.5% | 9.8% | 8.0% | 14.3% | 8.8% | 1.9% | 11.3% | 13.2% | 16.4% | 13.5% | 11.8% |
| Market Cap | 6.7B | 6.8B | 6.2B | 5.0B | 3.0B | 2.3B | 2.0B | 2.3B | 1.2B | 786M | 1.1B | 1.9B | 2.2B |
| Avg. Price | 58.57 | 74.03 | 67.21 | 55.94 | 47.26 | 27.03 | 18.20 | 28.06 | 20.47 | 13.34 | 10.19 | 15.80 | 26.26 |
| Year-End Price | 66.69 | 72.28 | 66.59 | 53.36 | 32.81 | 27.16 | 24.02 | 27.20 | 14.49 | 9.50 | 13.49 | 21.87 | 26.26 |
Pediatrix Medical Group, Inc. passes 4 of 9 quality checks, suggesting mixed fundamentals.
Pediatrix Medical Group, Inc. trades at 13.5x trailing earnings, compared to its 15-year median P/E of 16.6x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 8.1x vs a median of 9.5x. The company's 5-year average ROIC is 5.7%. Total shareholder yield (buybacks) is 4.9%. At current prices, the estimated annualized return to fair value is -4.6%.
Pediatrix Medical Group, Inc. (MD) reported annual revenue of $1.9 billion in its most recent fiscal year, based on SEC EDGAR filings.
Pediatrix Medical Group, Inc. (MD) has a net profit margin of 8.6%. This is a modest margin.
Pediatrix Medical Group, Inc. (MD) generated $253 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Pediatrix Medical Group, Inc. (MD) has a debt-to-equity ratio of 0.76. This indicates moderate leverage.
Pediatrix Medical Group, Inc. (MD) reported earnings per share (EPS) of $1.94 in its most recent fiscal year.
Pediatrix Medical Group, Inc. (MD) has a return on equity (ROE) of 20.3%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 18 years of financial data for Pediatrix Medical Group, Inc. (MD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Pediatrix Medical Group, Inc. (MD) has a book value per share of $10.16, based on its most recent annual SEC filing.